Palmitoylcarnitine impairs immunity in decompensated cirrhosis

In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondria...

Descripción completa

Detalles Bibliográficos
Autores: Wei Zhang, Ingrid, Sánchez-Rodríguez, María Belén, López-Vicario, Cristina, Casulleras, Mireia, Duran-Güell, Marta, Flores-Costa, Roger, Aguilar, Ferran, Rothe, Michael, Segalés, Paula, García-Ruiz, Carmen, Fernández-Checa, José C., Trebicka, Jonel, Arroyo, Vicente, Clària, Joan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/374201
Acceso en línea:http://hdl.handle.net/10261/374201
https://api.elsevier.com/content/abstract/scopus_id/85207272236
Access Level:acceso abierto
Palabra clave:Acute decompensation of cirrhosis
Acylcarnitines
Immune cells
Mitochondrial dysfunction
Descripción
Sumario:In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondrial dysfunction, are predictors of mortality in ACLF patients. Our hypothesis posits that acylcarnitines not only act as biomarkers, but also actively exert detrimental effects on circulating immune cells.

Similares en LA Referencia